Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab′)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab′)2 – implications for a PET theranostic strategy

Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab′)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab′)2 – implications for a PET theranostic strategy

Abstract Background Epidermal growth factor receptors (EGFR) are overexpressed on many head and neck squamous cell carcinoma (HNSCC). Radioimmunotherapy (RIT) with F(ab')2 of the anti-EGFR monoclonal antibody panitumumab labeled with the β-particle emitter, 177Lu may be a promising treatment fo...

Full description

Bibliographic Details
Main Authors: Anthony Ku, Misaki Kondo, Zhongli Cai, Jalna Meens, Min Rong Li, Laurie Ailles, Raymond M. Reilly
Format: Article
Language:English
Published: SpringerOpen 2021-08-01
Series:EJNMMI Radiopharmacy and Chemistry
Subjects:
Panitumumab
64Cu
177Lu
Dosimetry
Theranostics
Head and neck squamous cell carcinoma (HNSCC)
Online Access:https://doi.org/10.1186/s41181-021-00140-1

Internet

https://doi.org/10.1186/s41181-021-00140-1

Similar Items